Hormone News and Research

RSS

A hormone is a chemical released by one or more cells that affects cells in other parts of the organism. Only a small amount of hormone is required to alter cell metabolism. It is essentially a chemical messenger that transports a signal from one cell to another.

ANP reports positive interim results from ATL1103 Phase II clinical trial for acromegaly

Antisense Therapeutics Limited is pleased to advise that positive results have been achieved from the interim analysis of a subset of available data from its Phase II clinical trial of ATL1103 in patients with the growth disorder, acromegaly.

23 Dec 2013

Breast cancer patients experience fewer side effects on using aromatase inhibitor with sham acupuncture

Breast cancer patients experience fewer side effects while being treated with a widely used drug called an aromatase inhibitor when they get acupuncture - either the real treatment or a "sham" procedure, according to a new study led by researchers at the University of Maryland Marlene and Stewart Greenebaum Cancer Center.

23 Dec 2013

Real and sham weekly acupuncture treatments ease hot flashes of anticancer drug treatment

Both real and sham weekly acupuncture treatments eased hot flashes and other side effects of anticancer drug treatment in a small, preliminary study of breast cancer patients, Baltimore researchers have found.

23 Dec 2013

Type 2 diabetes in women less than 45 triples risk of early menopause

Type 2 diabetes - the most common type of diabetes - triples the risk of an early menopause in women younger than 45 years of age, according to new research published in the peer-reviewed journal Climacteric.

23 Dec 2013

Tomato-rich diet may help lower breast cancer risk in postmenopausal women

A tomato-rich diet may help protect postmenopausal women from breast cancer, according to new research published this week in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

22 Dec 2013

Lilly, Boehringer Ingelheim announce FDA acceptance of NDA filing for new insulin glargine product

Eli Lilly and Company and Boehringer Ingelheim today announced that the U.S. Food and Drug Administration has accepted the filing of the New Drug Application for LY2963016, an investigational basal (long-acting) insulin.

21 Dec 2013

Antares Pharma receives Notice of Allowance for new patent application on reconstitutable drugs

Antares Pharma, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent Office for application 13/584,317. This application, along with U.S. Patent 8,251,947 granted in August of 2012, relate to Antares' injector technology for wet-dry injectable drugs such as lyophilized biologicals or peptide drugs that require dry storage to assure stability.

20 Dec 2013

Researchers reveal how metabolic system breaks down in obesity

Researchers at University of Michigan have illuminated an aspect of how the metabolic system breaks down in obesity. The findings provide additional evidence that a drug entering clinical trials at the university could reverse obesity, Type 2 diabetes and fatty liver disease in humans.

20 Dec 2013

Study reveals why people are predisposed to cardiovascular disease and death

A genetic trait known to make some people especially sensitive to stress also appears to be responsible for a 38 percent increased risk of heart attack or death in patients with heart disease, scientists at Duke Medicine report.

19 Dec 2013

UCLA researchers find no evidence of association between iron levels and atherosclerosis risk

A UCLA research team has found no evidence of an association between iron levels in the body and the risk of atherosclerosis, the hardening and narrowing of the arteries that leads to cardiovascular disease, the No. 1 killer in the U.S.

18 Dec 2013

Endocrine Society issues scientific statement on health consequences of performance-enhancing drugs

A new Scientific Statement issued today by The Endocrine Society represents a comprehensive evaluation of available information on the prevalence and medical consequences of the use of performance-enhancing drugs. The statement highlights the clinical pharmacology, adverse effects and detection of many substances often classified as PEDs, identifies gaps in knowledge and aims to focus the attention of the medical community and policymakers on PED use as an important public health problem.

18 Dec 2013

New projects advance treatments for radiation syndrome, cardiac arrest-induced brain injury and rare blood disorder

The National Institutes of Health today has launched three pre-clinical projects to advance potential new treatments for acute radiation syndrome, brain injury following cardiac arrest and a rare blood disorder called beta thalassemia.

17 Dec 2013

Toddlers’ bedtime resistance may contribute to sleep problems

The bedtime you select for your toddler may be out of sync with his or her internal body clock, which can contribute to difficulties for youngsters attempting to settle in for the night, according to a new University of Colorado Boulder study.

17 Dec 2013

PAM50 FDA-cleared breast cancer test to be launched at ARUP Laboratories

The PAM50 breast cancer signature developed at the University of Utah and Huntsman Cancer Institute received FDA approval and will launch at ARUP Laboratories in Salt Lake City. The test utilizes gene expression data from 50 genes weighted together with clinical variables to generate a risk category and numerical score to assess a patient's risk of distant recurrence at ten years in postmenopausal women with node-negative (Stage I or II) or node-positive (Stage II), Hormone Receptor-Positive (HR+) breast cancer.

16 Dec 2013

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

The I-SPY 2 trial, an innovative, multidrug, phase II breast cancer trial, has yielded positive results with the first drug to complete testing in the trial. Adding the chemotherapy carboplatin and the molecularly targeted drug veliparib to standard presurgery chemotherapy improved outcomes for women with triple-negative breast cancer, according to results from the I-SPY 2 trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

16 Dec 2013

Combination of ramucirumab and docetaxel fails to delay advanced breast cancer progression

Adding the antibody therapy ramucirumab to the chemotherapy drug docetaxel did not delay disease progression for patients with HER2-negative, advanced breast cancer, according to results of a placebo-controlled, randomized, phase III clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

16 Dec 2013

UTHealth professor wins Founders' Laurel Award for exceptional service in the field of medical education

Arthur L. Day, M.D., professor of neurosurgery at The University of Texas Health Science Center at Houston and a neurosurgeon at the Mischer Neuroscience Institute at Memorial Hermann-Texas Medical Center, has received one of the top honors awarded by the Congress of Neurological Surgeons.

14 Dec 2013

Bisphosphonate zoledronate treatment not effective in women with chemoresistant breast cancer

Treatment with the bisphosphonate zoledronate did not improve outcomes for women with chemoresistant breast cancer, according to initial results of a phase III clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

14 Dec 2013

Study shows effectiveness of PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced new results from a combined analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Trans-Arimidex, Tamoxifen, Alone or in Combination (TransATAC) studies. These results, which evaluated samples from 2,137 patients, suggest that the PAM50-based Prosignaz Breast Cancer Prognostic Gene Signature Assay may help identify women with late distant recurrence after five years of endocrine treatment.

13 Dec 2013

Anastrozole drug reduces breast cancer in high risk post-menopausal women

Taking the breast cancer drug anastrozole for five years reduced the chances of post-menopausal women at high risk of breast cancer developing the disease by 53% compared with women who took a placebo, according to a study published in the Lancet today.

13 Dec 2013

Hormone News and Research

Further Reading

ANP reports positive interim results from ATL1103 Phase II clinical trial for acromegaly

Breast cancer patients experience fewer side effects on using aromatase inhibitor with sham acupuncture

Real and sham weekly acupuncture treatments ease hot flashes of anticancer drug treatment

Type 2 diabetes in women less than 45 triples risk of early menopause

Tomato-rich diet may help lower breast cancer risk in postmenopausal women

Lilly, Boehringer Ingelheim announce FDA acceptance of NDA filing for new insulin glargine product

Antares Pharma receives Notice of Allowance for new patent application on reconstitutable drugs

Researchers reveal how metabolic system breaks down in obesity

Study reveals why people are predisposed to cardiovascular disease and death

UCLA researchers find no evidence of association between iron levels and atherosclerosis risk

Endocrine Society issues scientific statement on health consequences of performance-enhancing drugs

New projects advance treatments for radiation syndrome, cardiac arrest-induced brain injury and rare blood disorder

Toddlers’ bedtime resistance may contribute to sleep problems

PAM50 FDA-cleared breast cancer test to be launched at ARUP Laboratories

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

Combination of ramucirumab and docetaxel fails to delay advanced breast cancer progression

UTHealth professor wins Founders' Laurel Award for exceptional service in the field of medical education

Bisphosphonate zoledronate treatment not effective in women with chemoresistant breast cancer

Study shows effectiveness of PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay

Anastrozole drug reduces breast cancer in high risk post-menopausal women

Viva Saliva Book: The ultimate guide to saliva Book preview Download eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News